Nexgen LPS Femoral and Tibial Knee components
Zimmer, Inc. · Decision date Jul 20, 2026
What did the FDA decide?
FDA records P060037/S098 as a supplement to PMA P060037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 20, 2026.
FDA approval order statement
introduction of Elma 9-Stage Nitric Immersion System for the Nexgen LPS Femoral and Tibial Knee components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Jul 20, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P060037/S098
- Regulatory pathway
- PMA supplement
- Applicant
- Zimmer, Inc.
- Product code
- NJL
- Decision code
- OK30
- Decision date
- Jul 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.
- Applicant
- Zimmer, Inc.
- Product code
- NJL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P060037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P060037 · Original PMA
NEXGEN LPS-FLEX MOBILE AND LPS-MOBILE BEARING KNEE SYSTEM
P060037/S095 · Related supplement
NexGen© LPSFlex/ LPS Mobile Bearing Knee System
P060037/S096 · Related supplement
NexGen LPS-Flex / LPS Mobile Bearing Knee System
P060037/S098 received
Application receipt date recorded by FDA.
P060037/S097 · Related supplement
Creep Pressure Test Update for the Nexgen LPS Bearing Knee
P060037/S098 · FDA decision
30-Day Notice
P060037/S099 · Related supplement
NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knee System
P060037/S100 · Related supplement
NexGen LPS-Flex/LPS Mobile Bearing Knee System
Timeline entries are records held by MedtechLedger for P060037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Zimmer, Inc. | PMA approval | Dec 10, 2007 | FDA | |
NexGen© LPSFlex/ LPS Mobile Bearing Knee SystemP060037/S095 | Zimmer, Inc. | PMA supplement | Aug 18, 2025 | FDA |
NexGen LPS-Flex / LPS Mobile Bearing Knee SystemP060037/S096 | Zimmer, Inc. | PMA supplement | Jan 16, 2026 | FDA |
| Zimmer, Inc. | PMA supplement | Jul 20, 2026 | FDA | |
| Zimmer, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
NexGen LPS-Flex/LPS Mobile Bearing Knee SystemP060037/S100 | Zimmer, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code NJL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LCS Knee SystemP830055/S378 | Depuy, Inc. | PMA supplement | Oct 27, 2026 | FDA |
| Depuy, Inc. | PMA supplement | Oct 27, 2026 | FDA | |
ATTUNE Revision Knee SystemP830055/S379 | Depuy, Inc. | PMA supplement | Oct 9, 2026 | FDA |
| Depuy, Inc. | PMA supplement | Oct 8, 2026 | FDA | |
LCS Total Knee SystemP830055/S380 | Depuy, Inc. | PMA supplement | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Zimmer, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- P.O. Box 708, Warsaw, IN, 46581
Sources and methodology
- Original FDA record: P060037/S098
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





